Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
62,457,444
-
Total 13F shares
-
70,701,088
-
Share change
-
-562,367
-
Total reported value
-
$6,174,669,356
-
Put/Call ratio
-
5.8%
-
Price per share
-
$87.34
-
Number of holders
-
306
-
Value change
-
+$99,663,604
-
Number of buys
-
159
-
Number of sells
-
143
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock, $0.00001 par value (PTGX) as of Q4 2025
As of 31 Dec 2025,
Protagonist Therapeutics, Inc - Common Stock, $0.00001 par value (PTGX) was held by
306 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
70,701,088 shares.
The largest 10 holders included
BlackRock, Inc., FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, RTW INVESTMENTS, LP, STATE STREET CORP, WELLINGTON MANAGEMENT GROUP LLP, UBS Group AG, JANUS HENDERSON GROUP PLC, JOHNSON & JOHNSON, and Invesco Ltd..
This page lists
306
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.